The Centre's decision to cap trade margins on 137 cancer medicines at 30 per cent has drawn widespread support across Karnataka's political spectrum, with both the ruling and opposition parties welcoming the move as a critical step toward making life-saving treatments more affordable. The price reduction, expected to take effect from 9 November, could bring down costs by up to 70 per cent for patients dependent on these drugs.

BJP Welcomes the Move

B.Y. Vijayendra, BJP Karnataka State President and MLA, on Monday, 19 October expressed gratitude to Prime Minister Narendra Modi and Union Health Minister J.P. Nadda on behalf of the people of Karnataka. He said the high cost of cancer treatment frequently pushes patients and their families into financial distress, and the Centre's intervention under Prime Minister Modi's leadership would meaningfully improve access to essential medicines.

'This is not just a reduction in medicine prices; it is another testament to the Modi government's concern for people's lives and livelihoods,' Vijayendra said.

He specifically highlighted that the cap would improve access to advanced therapies such as immunotherapy, particularly for patients from low and middle-income backgrounds.

Karnataka's Role in Flagging Price Disparities

The Centre's move comes partly in response to concerns raised at the state level. Karnataka Health and Family Welfare Minister U.T. Khader had earlier flagged significant price variations in cancer drugs manufactured by as many as 254 pharmaceutical companies. During inspections by the state's Food Safety and Drugs Administration (FDA), authorities found that medicines produced at relatively low costs were reaching consumers at substantially higher maximum retail prices (MRPs).

'Taking this issue seriously, I had instructed FDA officials to examine the price variations in medicines and initiate appropriate action,' Khader said. His office also directed officials to bring the matter to the attention of central bodies, including the National Pharmaceutical Pricing Authority (NPPA) and the Central Drugs Standard Control Organisation (CDSCO).

Khader had publicly raised the issue at Bengaluru's Arogya Soudha on 9 September, urging the Union government to act in the interest of patients. The data on price variations, landing costs, and consumer-level prices was subsequently compiled and submitted with supporting documents to central authorities.

PIL and Judicial Attention

The issue of cancer drug price disparities has also reached the Supreme Court, through a Public Interest Litigation (PIL) that Khader described as a significant development bringing medicine price inequities to judicial notice. The minister also acknowledged the role of the media in generating public discussion that helped accelerate regulatory attention.

What the Price Cap Means for Patients

The trade margin cap limits the cumulative markup that distributors and retailers can add to the manufacturer's price, directly compressing the gap between production cost and consumer-level MRP. For cancer patients — who often require sustained, expensive regimens — even a modest percentage reduction in drug costs can translate into substantial annual savings. The 70 per cent reduction in some medicine prices, expected from 9 November, is likely to ease the burden most sharply for those on immunotherapy protocols, which rank among the costliest cancer treatments currently available.

With the regulation set to take effect in weeks, patient advocacy groups and oncologists will be watching closely to see whether the projected price cuts materialise uniformly across pharmacies and hospital dispensaries.